drugset / Trial / NCT05513391

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

NCT05513391

Phase 3 Terminated 366 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study was to demonstrate the non-inferior HAI immune response of quadrivalent recombinant influenza vaccine (RIV4) vs licensed Egg-Based Quadrivalent Influenza Vaccine (IIV4) for the 4 strains based on the egg-derived antigen in all participants aged 3 to 8 years and to describe the immunogenicity and safety profile of RIV4 compared to IIV4 in participants aged 3 to 8 years.

Timeline

Start
2022-11-10
Primary completion
2023-10-03
Completion
2023-10-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Flublok Vaccine Intramuscular
Comparator Quadrivalent influenza vaccine Vaccine Intramuscular

Indications

No indication recorded.